- Received November 15, 2021
- Accepted December 13, 2021
- Publication February 15, 2022
- Visibility 12 Views
- Downloads 2 Downloads
- DOI 10.18231/j.ijogr.2022.009
-
CrossMark
- Citation
Investigating the relationship between Vitamin D level and Polycystic ovarian syndrome- A case control study
Introduction
Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age, the prevalence ranging from 9 to 18%.[1], [2] Common features of PCOS are obesity, hyperandrogenemia, and insulin resistance (IR).[3] Studies have confirmed the relationship between PCOS and type 2 diabetes mellitus (T2DM), cardiovascular disease and metabolic syndrome.[4], [5]
30–40% of PCOS women have IR and compensatory hyperinsulinaemia, of which ~10% develop T2DM.[6] Dyslipidaemia, comprising higher concentrations of triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C), and lower concentrations of high-density lipoprotein cholesterol (HDLC), are more prevalent in PCOS than in healthy women.[7]
Vitamin D, a steroid hormone, is essential in skeletal growth and development, calcium/phosphorus metabolism, and bone mineralization.[8], [9] Vitamin D receptors regulate the expression of 229 genes in ~ 30 different tissues, including the pancreas, liver, immune cells, brain and ovaries.[9] The difference of vitamin D levels between PCOS women and healthy women, and the relationship between vitamin D and metabolic factors in PCOS women has remained controversial.
Some studies have shown that PCOS women have vitamin D deficiency unlike age matched healthy women. Moreover, vitamin D deficiency is associated with homeostasis model assessment of insulin resistance (HOMA-IR), hyperinsulinaemia, dyslipidaemia, and metabolic risk factors in patients with PCOS.[10], [11] However, other studies show different results.[12]
This case control study aims to investigate vitamin D status between PCOS and non-PCOS subjects and analyze the relationship between vitamin D deficiency and metabolic risk factors in women with PCOS.
Materials and Methods
Study design and participants
This survey was a case - control study. A total of 49 women, diagnosed with PCOS, were recruited from the gynecological clinic of JIMS Hospital, Kolkata from July 2020 to June 2021. 49 age-matched women without PCOS were selected as controls. The modified Rotterdam criteria was used for diagnosing PCOS.[13] Women with hypothyroidism and hyperprolactinemia were excluded. The protocol was approved by the Institutional Review Board.
Outcome measures
Basic information, collected through questionnaire, included age, body mass index (BMI), and blood pressure. BMI >/= 28.0 kg/m2 was defined as obesity.[14] All biochemical indicators were tested in our hospital including serum 25-hydroxyvitamin D[25(OH)D], follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), testosterone (T), fasting blood glucose, fasting insulin and lipid profile. HOMA-IR was calculated to evaluate insulin resistance (IR). HOMAIR = [fasting glucose(mmol/L) × fasting insulin(mIU/L)]/ 22.5. HOMA-IR > 2.5 was defined as IR.[15] Serum vitamin D levels <20 ng/mL, 20 - 30 ng/mL and >/= 30 ng/mL were defined as deficiency, insufficiency and normal respectively.[16]
The primary outcome was the difference in vitamin D level between the PCOS and control groups. The secondary outcome was the correlation between serum vitamin D concentration and metabolic risk factors in PCOS women.
Statistical analysis of data
Data was analyzed by SPSS (version 27.0). Data had been summarized as mean and standard deviation for numerical variables and count and percentages for categorical variables. Two-sample t-tests for a difference in mean involved independent samples or unpaired samples. One-way analysis of variance (one-way ANOVA) was used to compare means of three or more samples for numerical data.
Results
|
Characteristic |
Case n=49 |
Control n=49 |
p-value |
|
Age |
23.78±5.67 |
27.45±5.45 |
0.001 |
|
BMI |
25.35±5.44 |
23.11±2.81 |
0.013 |
|
SBP (systolic BP) |
113.67±10.74 |
127.35±6.38 |
0.000 |
|
DBP (diastolic BP) |
73.59±8.30 |
69.84±8.61 |
0.030 |
|
LH/FSH |
2.61±4.91 |
2.80±4.89 |
0.846 |
|
Testosterone |
22.98±22.37 |
28.31±21.92 |
0.236 |
|
PRL |
15.24±5.18 |
15.05±5.04 |
0.854 |
|
Vit D Level |
19.40±11.49 |
28.81±10.73 |
0.0001 |
|
Fast Insulin |
11.63±16.01 |
13.47±19.30 |
0.609 |
The differences in age, BMI, SBP, DBP, and PRL were found to be statistically significant (p value <.05). No statistically significant differences could be found in the other parameters between the two groups.
Vitamin D level status between PCOS women and controls
The serum 25(OH) D concentration was significantly lower in PCOS women than in controls (19.3967± 11.4876.vs. 28.8120± 10. 7247.p<0.0001) ([Table 1], [Figure 3]). In addition, the prevalence rates of 25(OH)D deficiency and insufficiency were significantly higher in women with PCOS than in controls (65.3% vs. 18.4%, P <0.01; 26.5%) % vs. 22.4%, P < 0.0001). ([Figure 4]). Furthermore, the prevalence of normal 25(OH)D status in women with PCOS was significantly lower than that in controls (8.2% vs. 59.2%, P < 0.01).
|
Metabolic Factor |
Deficiency (n=32) |
Insufficiency (n=13) |
Normal (n=4) |
p-value |
|
BMI |
25.72±5.07 |
24.91±6.10 |
23.77±7.37 |
0.760 |
|
Fast Insulin |
13.70±19.50 |
7.93±2.90 |
7.06±2.25 |
0.469 |
|
Insulin Resistance (IR) |
4.09±3.80 |
1.42±0.42 |
1.52±0.49 |
0.026 |
[Table 2] llustrates the difference in the metabolic factors(BMI, Fasting Insulin, and IR) between the 3 subgroups of deficiency, insufficiency and normal Vit D level among the PCOS patients. Only the difference in IR was found to be statistically significant. (P value <0.05).
|
Metabolic parameters |
Vit D Deficiency (n=32) |
Vit D Insufficiency (n=13) |
Normal Vit D (n=4) |
p-value |
|
Obese (BMI>28kg/M2) |
18 (66.67%) |
7 (25.93%) |
2 (0.54%) |
0.967 |
|
Non-obese (BMI <28kg/M2) |
14 (63.6%) |
6 (27.27%) |
2 (9.1%) |
|
|
Lipid profile deranged |
21 (75%) |
6 (21.43%) |
1 (4.55%) |
0.195 |
|
Lipid profile normal |
11(52.38%) |
7 (33.33%) |
3(14.28%) |
|
|
Insulin resistance present |
26 (100%) |
0 |
0 |
0.000 |
|
insulin resistance absent |
6 (26.1%) |
13 (56.5%) |
4 (17.4%) |
[Table 3] shows theprevalence of obesity, abnormal lipid profile and HOMA – IR among different vitamin D categories in women with PCOS. There was statistically significant difference in HOMA-IR, among the three groups (P < 0.05). No significant difference was found when comparing prevalence of obesity and deranged lipid profile among different groups (P > 0.05). The same is portrayed in the 3 figures below ([Figure 5], [Figure 6], [Figure 7]).
|
Lipid derangement type n=22 |
Deficiency (n=33) |
Insufficiency (n=13) |
Normal (n=4) |
p-value |
|
Cholesterol n=8 |
5 (62.5%) |
3 (37.5%) |
0 (0%) |
0.191 |
|
HDL n=2 |
1 (50%) |
0 (0%) |
1 (50%) |
0.028 |
|
LDL n=7 |
6 (85.7%) |
1 (14.28%) |
0 (0%) |
0.160 |
|
VLDL n=1 |
1 (100%) |
0 (0%) |
0 (0%) |
0.221 |
|
Triglyceride n=4 |
3 (75%) |
1 (25%) |
0 (0%) |
0.241 |
[Table 4] shows that 62.5% of those PCOS women with hypercholesterolemia, 50% with increased HDL cholesterol, 85.7% with increased LDL, 100% with increased VLDL and 75% with increased triglycerides hadVit D deficiency. Also, excepting for 1 person with increased HDL, none of those PCOS women with normal Vit D level had any lipid derangements. (Fig 3).
Discussion
More than one billion children and adults in the world have vitamin D deficiency.[17] Among PCOS women, there is a higher prevalence of vitamin D deficiency compared to non- PCOS women, and this deficiency is associated with ovulatory dysfunction, IR and hyperandrogenism [18]. Our study showed significantly lower levels of vitamin D among cases; moreover, the prevalence rates of 25(OH)D deficiency and insufficiency were significantly higher in women with PCOS than in controls, similar to a previous study.[19]
Multiple observational studies have shown that low vitamin D concentration is associated with increased BMI, IR, testosterone and dehydroepiandrosterone sulfate (DHEAS) levels in women with PCOS22. In our study, serum 25(OH)D concentration was found to be significantly lower in PCOS women with IR than in PCOS women without IR. In addition, the prevalence of 25(OH)D deficiency in PCOS women with IR was significantly higher than in women without IR. Epidemiological studies have confirmed that vitamin D status is negatively associated with diabetes, which may be multifactorial. Research confirmed that 25(OH)D increases the expression of insulin receptors, and inhibits the release of inflammatory cytokines that are proved to cause IRS.[20] Studies have reported that vitamin D indirectly improves function of insulin through regulation of extracellular calcium.[21] However, other researchers like Ng et al. demonstrated that there was no statistically significant correlation between vitamin D level and BMI, WHR, and metabolic parameters among PCOS women. [12] In our study, lipid profile derangement regarding HDL – cholesterol was significantly more prevalent in vitamin D deficiency group among cases. This finding was concordant with the results of previous studies.[22]
Clinical manifestations of PCOS include obesity, metabolic syndrome and chronic inflammation, which are related to vitamin D deficiency.[23], [24], [25], [26] Our findings revealed that serum 25(OH)D level in PCOS women was significantly negatively- correlated with HOMAIR, however, there was no significant correlation with obesity. This could be explained by small sample size and rural settings of the study with most of the population having generalized malnutrition.
Treatment with vitamin D was shown to improve the follicular development, menstrual cycle regulation, insulin resistance, and hyperandrogeni.[12] However, Xue et al. showed that vitamin D supplementation did not change the HOMA-IR, LDL, DHEAS, free testosterone, and total testosterone in women with PCOS.[27] Conflicting results may be related to sample size, vitamin D supplement dose, participant habits, and place of residence. Therefore, multi-center randomized controlled trials with large sample sizes are required to explore the metabolic role of vitamin D supplementation in women with PCOS.
Conclusion
PCOS women are more prone to vitamin D deficiency than normal subjects. Increased Insulin resistance and increased HDL- C are significantly more common in the Vitamin D deficiency group among PCOS women.
Limitations
The sample size of the participants was relatively small and it was wholly rural based single center study in the suburbs of Kolkata, eastern India. The result of this research needs to be proved through multi-center surveys with larger sample sizes in other areas in India.
Source of Funding
This study was not aided by any grants.
Conflict of Interest
None.
References
- WA March, VM Moore, KJ Willson, DI Phillips, RJ Norman, MJ Davies. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010. [Google Scholar]
- . The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS). Hum Reprod 2012. [Google Scholar]
- SS Lim, MJ Davies, RJ Norman, LJ Moran. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2012. [Google Scholar]
- BC Fauser, BC Tarlatzis, RW Rebar, RS Legro, AH Balen, R Lobo. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012. [Google Scholar]
- KD Domenico, D Wiltgen, FJ Nickel, JA Magalhães, RS Moraes, PM Spritzer. Cardiac autonomic modulation in polycystic ovary syndrome: does the phenotype matter?. Fertil Steril 2013. [Google Scholar]
- LJ Moran, ML Misso, RA Wild, RJ Norman. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010. [Google Scholar]
- RA Wild, M Rizzo, S Clifton, E Carmina. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 2011. [Google Scholar]
- MF Holick. Vitamin D defi ciency. N Engl J Med 2007. [Google Scholar]
- D Gatti, L Idolazzi, A Fassio. Vitamin D: Not just bone, but also immunity. Minerva Med 2016. [Google Scholar]
- HW Li, RE Brereton, RA Anderson, AM Wallace, CK Ho. Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. Metabolism 2011. [Google Scholar]
- AE Joham, HJ Teede, S Cassar, NK Stepto, BJ Strauss, CL Harrison. Vitamin D in polycystic ovary syndrome: relationship to obesity and insulin resistance. Mol Nutr Food Res 2016. [Google Scholar]
- BK Ng, CL Lee, PS Lim, H Othman, NAM Ismail. Comparison of 25- hydroxyvitamin D and metabolic parameters between women with and without polycystic ovarian syndrome. Horm Mol Biol Clin Investig 2017. [Google Scholar] [Crossref]
- ZJ Chen, Y Shi, Y Sun, B Zhang, X Liang, Y Cao. Fresh versus frozen embryos for infertility in the polycystic ovary syndrome. N Engl J Med 2016. [Google Scholar]
- L Li, F Zhang, J Cui, Y Shi, J Xiang, X Wang. Association of betatrophin with metabolic characteristics in overweight/obese and lean women with PCOS. Gynecol Endocrinol 2017. [Google Scholar]
- M Jamilian, F Foroozanfard, E Rahmani, M Talebi, F Bahmani, Z Asemi. Effect of two different doses of vitamin D supplementation on metabolic profiles of insulin-resistant patients with polycystic ovary syndrome. Nutrients 2017. [Google Scholar]
- CF Yun, J Chen, Y He, D Mao, R Wang, Y Zhang. Vitamin D deficiency prevalence and risk factors among pregnant Chinese women. Public Health Nutr 2017. [Google Scholar]
- MF Holick. The vitamin D deficiency pandemic: approaches for diagnosis, treatment and prevention. Rev Endocr Metab Disord 2017. [Google Scholar]
- RL Thomson, S Spedding, JD Buckley. Vitamin D in the aetiology and management of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2012. [Google Scholar]
- YHM Krul-Poel, PP Koenders, RP Steegers-Theunissen, ET Boekel, MM Terwee, Y Louwers. Vitamin D and metabolic disturbances in polycystic ovary syndrome(PCOS): a cross-sectional study. PLoS One 2018. [Google Scholar]
- D Teegarden, SS Donkin. Vitamin D: emerging new roles in insulin sensitivity. Nutr Res Rev 2009. [Google Scholar]
- AG Pittas, J Lau, FB Hu, B Dawson-Hughes. The role of vitamin D and calcium in type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2007. [Google Scholar]
- E Wehr, S Pilz, N Schweighofer, A Giuliani, D Kopera, TR Pieber. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol 2009. [Google Scholar]
- T Skaaby, B H Thuesen, A Linneberg. Vitamin D, cardiovascular disease and risk factors. Adv Exp Med Biol 2017. [Google Scholar]
- F Sassi, C Tamone, P D’Amelio. Vitamin D: nutrient, hormone, and immunomodulator. Nutrients 2018. [Google Scholar]
- HW Li, RE Brereton, RA Anderson, AM Wallace, CK Ho. Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. Metabolism 2011. [Google Scholar]
- AE Joham, HJ Teede, S Cassar, NK Stepto, BJ Strauss, CL Harrison. Vitamin D in polycystic ovary syndrome: relationship to obesity and insulin resistance. Mol Nutr Food Res 2016. [Google Scholar]
- CE Chagas, MC Borges, LA Martini, MM Rogero. Focus on vitamin D, inflammation and type 2 diabetes. Nutrients 2012. [Google Scholar]